Mallinckrodt (MNK) Tops Q1 EPS by 13c, Revenues Beat; Raises FY19 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mallinckrodt plc (MNK) PT Lowered to $35 at BMO Capital
May 7, 2019 3:56 PM EDTBMO Capital analyst Gary Nachman lowered the price target on Mallinckrodt plc (NYSE: MNK) to $35.00 (from $37.00) while maintaining a Outperform rating.
The analyst commented, "MNK delivered solid 1Q19 results as strong performance across hospital franchise and Specialty Generics/Amitiza more-than-offset some... More
Put Buying Activity in Mallinckrodt (MNK) Targets 23% Downside in Shares Through Jan. 2021 -Susquehanna
May 7, 2019 1:50 PM EDTSusquehanna options strategist Alison Edwards Mallinckrodt notes bearish options activity in (NYSE: MNK), as an opening investor bought 7k Jan2021 20 Puts, paying $7.55. The investor suggests the shares have an increased probability to remain below $20 through Jan 20201 and breaks even on a ~23% move lower.... More
Mallinckrodt Plc (MNK), Cancer Prevention Pharmaceuticals Report Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac
May 7, 2019 6:23 AM EDTMallinckrodt Plc (NYSE: MNK) and Cancer Prevention Pharmaceuticals, Inc. (CPP) today announced that CPP's pivotal phase 3 clinical trial, CPP FAP-310, of the investigational drug CPP-1X/sulindac in patients with familial adenomatous polyposis (FAP), did not meet its primary endpoint. Specifically, the reduction of time to the first occurrence of an FAP-related event for the combination of CPP-1X (eflornithine) and sulindac (a nonsteroidal anti-inflammatory drug) did not reach statistical significance compared to the two control arms. CPP FAP-310 included only active comparator arms and was the largest and longest study ever... More
Mallinckrodt (MNK) Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax Gas for Inhalation for PH in Neonates
May 6, 2019 6:50 AM EDTMallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced preliminary results of a planned interim analysis from the company's Phase 4 registry assessing the use of INOmax® (nitric oxide) gas, for inhalation, for premature (27 to less than 34 weeks gestational age) neonates versus term and near-term neonates (34 weeks and greater gestational age) with pulmonary hypertension (PH).
The primary outcome measure compares the incidence of... More
